GAITHERSBURG, Md., Feb 22, 2005 /PRNewswire-FirstCall via COMTEX/ -- MedImmune, Inc.
(Nasdaq: MEDI) announced today that Linda J. Peters has joined the management
team as senior vice president, regulatory affairs. In addition, several
existing members of the team have been promoted and assumed additional
management responsibilities. Promotions include: Armando Anido, R.Ph.,
executive vice president, sales and marketing; Bernardus N.M. Machielse, Drs.,
senior vice president, operations; Edward T. Mathers, senior vice president,
corporate development; Peter A. Kiener, D.Phil., senior vice president,
research; and Charles F. Katzer, vice president, vaccine manufacturing.
"MedImmune continues to attract and develop world-class management
talent," said David M. Mott, chief executive officer and president. "Linda
Peters brings tremendous regulatory experience and outstanding general
management skills to our regulatory affairs team. The promotions of Armando
Anido, Ed Mathers, Peter Kiener and Chuck Katzer reflect their growth and
increasing contributions to our business. The promotion of Ben Machielse
reflects his outstanding contributions to our business and supports the
organizational objective of creating a more efficient and collaborative
operations team among the manufacturing, supply chain and quality
organizations. We are fortunate to have each of these outstanding
professionals on our leadership team."
New Senior Appointment
Linda J. Peters joins MedImmune as senior vice president, regulatory
affairs where she will be responsible for defining and orchestrating the
company's global regulatory strategy. Prior to joining the company, Ms.
Peters was vice president of global regulatory affairs for the Bioscience and
Renal Divisions of Baxter Healthcare. While at Baxter, she was responsible for
implementing global regulatory strategies for biologics, vaccines, drugs,
biosurgical products and devices, which included several new product approvals
worldwide. Previously, Ms. Peters was director, regulatory affairs for Takeda
Pharmaceuticals North America where she was responsible for the regulatory
management of more than a dozen new compounds and marketed products. As the
first regulatory affairs scientist at Takeda, she created a regulatory vision
for the company and successfully established a department of more than 30
regulatory professionals in less than three years. Ms. Peters was also
involved with the U.S. approval and launch of ACTOS (pioglitazone HCl), a drug
for the treatment of Type II diabetes. In addition, she held positions of
increasing responsibility at TAP Pharmaceuticals, which included regulatory
approval for several new indications for PRECAVID (lansoprazole), an anti-
ulcer drug. Ms. Peters earned her bachelor of science and master of science
degrees in animal science from Southern Illinois University. She also holds a
master of business administration degree from the J.L. Kellogg School of
Management at Northwestern University. In her new role at MedImmune, Ms.
Peters will report to James F. Young, Ph.D., president, research and
As executive vice president, sales and marketing, Armando Anido is
responsible for overseeing the company's global commercial activities. He
also plays an integral role in defining the strategic vision of the company.
Anido joined MedImmune in 1999 as senior vice president, sales and marketing.
Prior to joining MedImmune, Mr. Anido was vice president of CNS Marketing at
Glaxo Wellcome, Inc. During his time with Glaxo Wellcome, Mr. Anido had
profit and loss responsibility for a CNS business, managed the CNS marketing
team, and was directly responsible for the launches of seven products/line
extensions within 24 months. Mr. Anido also held various positions at Lederle
Laboratories, culminating in his service as the vice president of anti-
infectives marketing. Mr. Anido is a registered pharmacist, and holds a
bachelor's degree in pharmacy and a master of business administration from
West Virginia University.
Edward T. Mathers is MedImmune's senior vice president, corporate
development, where he is responsible for the company's licensing and business
development activities. He also works closely with our MedImmune Ventures
team on the evaluation of investment opportunities. Prior to joining
MedImmune in 2002, Mr. Mathers was vice president of marketing and corporate
licensing and acquisitions at Inhale Therapeutic Systems. Previously, he
enjoyed a successful 15-year career at Glaxo Wellcome, Inc., holding a number
of increasingly responsible positions in sales and marketing. Mr. Mathers
began his career as a researcher at Ortho Pharmaceuticals Corporation, a
division of Johnson & Johnson. Mr. Mathers holds a bachelor's degree in
chemistry from North Carolina State University.
As senior vice president, research, Dr. Peter Kiener oversees the
company's global research activities. Prior to joining MedImmune in 2001, Dr.
Kiener spent 18 years with Bristol-Myers Squibb's Pharmaceutical Research
Division. Previously, Dr. Kiener spent several years in the academic setting
as an assistant professor at the University of North Texas/Texas College of
Osteopathic Medicine's Department of Anatomy; as a research associate at the
Department of Biochemistry, University of Massachusetts (Amherst); and, as a
postdoctoral research assistant, Medical Research Council, Sir William Dunn
School of Pathology, University of Oxford. Dr. Kiener holds a bachelor of
science degree with honors in chemistry from Lancaster University, Lancaster,
the United Kingdom, and a doctorate of philosophy in biochemistry from the
Oxford University, Sir William Dunn School of Pathology, Oxford, England.
Expanded Management Responsibilities in Operations
In January 2005, Drs. Bernardus N.M. Machielse, senior vice president,
operations, assumed responsibility for all manufacturing and supply chain
operations, in addition to his responsibility for MedImmune's quality
operations. The expansion of Drs. Machielse's role reflects his significant
contributions to MedImmune and particularly to its quality, manufacturing and
operations functions since he joined the company in May 1999. During his
tenure he has led the growth of the quality department from 80 to more than
250 people, including the incorporation of the quality-related activities from
the U.S. Bioscience and Aviron acquisitions. Prior to joining MedImmune, Drs.
Machielse was vice president, quality control and quality assurance, for Xoma
Corporation. He also spent several years in various manufacturing and quality
positions at Centocor BV of the Netherlands. Drs. Machielse holds a bachelor
of science degree in medical biology and a master of science degree in
biochemistry from the University of Utrecht, the Netherlands.
In January 2005, Charles F. Katzer, vice president, vaccine manufacturing
assumed responsibility for the company's global vaccine manufacturing
operations. Previously, Mr. Katzer was vice president and site director of
manufacturing activities in Pennsylvania. Prior to joining MedImmune in 2000,
Mr. Katzer served as vice president, operations for U.S. Bioscience, Inc.
Earlier in his career, he was senior director, operations for Immunomedics and
held numerous management positions for Rhone Poulenc Rorer, McGaw
Laboratories, Baxter Travenol Laboratories and Biological Specialties. Mr.
Katzer received his bachelor's degree in zoology from the University of
Wisconsin where he also served as a research assistant in parasitology.
About MedImmune, Inc.
MedImmune strives to provide better medicines to patients, new medical
options for physicians, rewarding careers to employees, and increased value to
shareholders. Dedicated to advancing science and medicine to help people live
better lives, the company is focused on the areas of infectious diseases,
cancer and inflammatory diseases. With approximately 2,000 employees
worldwide, MedImmune is headquartered in Maryland. For more information, visit
the company's website at http://www.medimmune.com.
This announcement may contain, in addition to historical information,
certain forward-looking statements that involve risks and uncertainties. Such
statements reflect management's current views and are based on certain
assumptions. Actual results could differ materially from those currently
anticipated as a result of a number of factors, including risks and
uncertainties discussed in MedImmune's filings with the U.S. Securities and
Exchange Commission. The company is developing several products for potential
future marketing. There can be no assurance that such development efforts
will succeed, that such products will receive required regulatory clearance or
that, even if such regulatory clearance were received, such products would
ultimately achieve commercial success.
SOURCE MedImmune, Inc.
Media: Jamie Lacey +1-301-398-4035 or Clarencia Stephen +1-301-398-4073
Investors: Peter Vozzo +1-301-398-4358 or John Filler +1-301-398-4086all of